Browse DENND1C

Summary
SymbolDENND1C
NameDENN/MADD domain containing 1C
Aliases FLJ22757; connecdenn 3; FAM31C; family with sequence similarity 31, member C; Protein FAM31C; DENN domain-co ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytosol Cytoplasmic vesicle, clathrin-coated vesicle
Domain PF03455 dDENN domain
PF02141 DENN (AEX-3) domain
PF03456 uDENN domain
Function

Guanine nucleotide exchange factor (GEF) which may activate RAB8A, RAB13 and RAB35. Promotes the exchange of GDP to GTP, converting inactive GDP-bound Rab proteins into their active GTP-bound form.

> Gene Ontology
 
Biological Process -
Molecular Function GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0017112 Rab guanyl-nucleotide exchange factor activity
Cellular Component GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-199991: Membrane Trafficking
R-HSA-8876198: RAB GEFs exchange GTP for GDP on RABs
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolDENND1C
NameDENN/MADD domain containing 1C
Aliases FLJ22757; connecdenn 3; FAM31C; family with sequence similarity 31, member C; Protein FAM31C; DENN domain-co ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DENND1C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolDENND1C
NameDENN/MADD domain containing 1C
Aliases FLJ22757; connecdenn 3; FAM31C; family with sequence similarity 31, member C; Protein FAM31C; DENN domain-co ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DENND1C in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDENND1C
NameDENN/MADD domain containing 1C
Aliases FLJ22757; connecdenn 3; FAM31C; family with sequence similarity 31, member C; Protein FAM31C; DENN domain-co ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DENND1C in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1830.715
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0750.944
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2580.776
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8340.0361
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.1520.619
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4330.883
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5680.183
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.2180.201
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1640.878
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3760.809
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2360.918
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2570.191
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DENND1C in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolDENND1C
NameDENN/MADD domain containing 1C
Aliases FLJ22757; connecdenn 3; FAM31C; family with sequence similarity 31, member C; Protein FAM31C; DENN domain-co ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DENND1C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDENND1C
NameDENN/MADD domain containing 1C
Aliases FLJ22757; connecdenn 3; FAM31C; family with sequence similarity 31, member C; Protein FAM31C; DENN domain-co ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DENND1C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DENND1C.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDENND1C
NameDENN/MADD domain containing 1C
Aliases FLJ22757; connecdenn 3; FAM31C; family with sequence similarity 31, member C; Protein FAM31C; DENN domain-co ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DENND1C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDENND1C
NameDENN/MADD domain containing 1C
Aliases FLJ22757; connecdenn 3; FAM31C; family with sequence similarity 31, member C; Protein FAM31C; DENN domain-co ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DENND1C expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDENND1C
NameDENN/MADD domain containing 1C
Aliases FLJ22757; connecdenn 3; FAM31C; family with sequence similarity 31, member C; Protein FAM31C; DENN domain-co ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DENND1C and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDENND1C
NameDENN/MADD domain containing 1C
Aliases FLJ22757; connecdenn 3; FAM31C; family with sequence similarity 31, member C; Protein FAM31C; DENN domain-co ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DENND1C collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.